In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours

BACKGROUND: Targeted therapies elicit anticancer activity by exerting pharmacodynamic effects on specific molecular targets. Currently, there is limited use of pharmacodynamic assessment to guide drug administration in the routine oncology setting. METHODS: We developed a phosphoshift (pShift) flow...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintela-Fandino, M, Krzyzanowska, M, Duncan, G, Young, A, Moore, M J, Chen, E X, Stathis, A, Colomer, R, Petronis, J, Grewal, M, Webster, S, Wang, L, Siu, L L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619253/
https://www.ncbi.nlm.nih.gov/pubmed/23412107
http://dx.doi.org/10.1038/bjc.2013.64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619253/
https://www.ncbi.nlm.nih.gov/pubmed/23412107
http://dx.doi.org/10.1038/bjc.2013.64

Ejemplares similares